Xeno Biosciences initiate phase 1b proof-of-concept study for obesity drug candidate XEN-101
Xeno Biosciences has initiated a Phase 1b clinical study designed to provide proof-of-concept weight loss results, along with safety and...
top of page
Browse by category
Search
Browse by tag
bottom of page